Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rimonabant--a selective CB1 antagonist.

Steven Thomas Boyd1, Brad Allen Fremming

  • 1Department of Pharmacy Practice, School of Pharmacy and Health Professionals, Creighton University, Omaha, NE 67178-0401, USA. sboys@creighton.edu

The Annals of Pharmacotherapy
|March 10, 2005
PubMed
Summary

Rimonabant, a selective cannabinoid receptor antagonist, shows promise for treating obesity and aiding smoking cessation. Further research is exploring its potential for metabolic syndrome and alcohol abuse.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Update on rimonabant--a selective cannabinoid CB1 antagonist.

The Annals of pharmacotherapyยท2006
See all related articles

Area of Science:

  • Pharmacology and Therapeutics
  • Endocannabinoid System Research

Background:

  • Rimonabant is a novel selective antagonist of the cannabinoid receptor type 1 (CB1).
  • The endocannabinoid system plays a role in appetite regulation and addiction pathways.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant.
  • To assess the potential therapeutic applications of rimonabant in obesity, smoking cessation, and metabolic syndrome.

Main Methods:

  • A comprehensive literature search was conducted using MEDLINE (1966-November 2004) and bibliographies.
  • Key search terms included obesity, smoking cessation, cannabinoid, and rimonabant.
  • Relevant studies and review articles on rimonabant and the endocannabinoid system were included.

Main Results:

  • Rimonabant demonstrated beneficial effects in preclinical and clinical studies for obesity and smoking cessation.
  • Animal studies indicated reduced hunger, caloric intake, and body weight, with increased satiety.
  • Human trials suggest efficacy in treating obesity and smoking cessation; nausea was the most common adverse effect, slightly exceeding placebo.

Conclusions:

  • Rimonabant represents a new class of drugs: selective cannabinoid CB1 receptor antagonists.
  • The drug showed potential for treating obesity and smoking cessation, with possible approval anticipated.
  • Ongoing studies are investigating additional clinical uses, including metabolic syndrome and alcohol abuse.

Related Experiment Videos